

Georgina V Long

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1866005/publications.pdf>

Version: 2024-02-01

528
papers

89,044
citations

944

115
h-index

350

284
g-index

535
all docs

535
docs citations

535
times ranked

53365
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
2	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
3	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
4	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
5	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
6	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
7	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	13.9	2,445
8	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
9	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
10	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
11	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	3.4	1,625
12	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
13	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
14	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
15	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	6.3	1,175
16	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017, 170, 1109-1119.e10.	13.5	1,124
17	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	13.7	1,068
18	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862.	6.3	1,032

#	ARTICLE	IF	CITATIONS
19	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
20	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1239-1246.	0.8	942
21	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
22	Antibacterial agents based on the cyclic d,l- α -peptide architecture. <i>Nature</i> , 2001, 412, 452-455.	13.7	910
23	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
24	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet</i> , The, 2012, 379, 1893-1901.	6.3	856
25	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	5.1	841
26	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. <i>Cancer Discovery</i> , 2014, 4, 80-93.	7.7	836
27	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	0.8	829
28	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	5.1	812
29	Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 386, 24-34.	13.9	766
30	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	5.1	732
31	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	0.6	641
32	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	5.1	611
33	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1386-1394.	3.2	589
34	Melanoma whole-exome sequencing identifies V600E-BRAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	5.8	567
35	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	5.1	561
36	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	0.6	549

#	ARTICLE	IF	CITATIONS
37	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
38	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	3.4	534
39	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , The, 2018, 19, 310-322.	5.1	486
40	Immune checkpoint inhibitors in melanoma. <i>Lancet</i> , The, 2021, 398, 1002-1014.	6.3	462
41	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	3.2	447
42	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
43	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	0.8	439
44	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017, 52, 71-81.	3.4	437
45	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3242-3249.	3.2	405
46	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	5.1	399
47	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3205-3211.	0.8	395
48	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 245-253.	1.5	356
49	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 487-504.	3.2	355
50	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	5.1	346
51	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1767-1774.	0.8	335
52	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	0.6	304
53	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	3.2	297
54	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. <i>Nature Communications</i> , 2014, 5, 5694.	5.8	295

#	ARTICLE	IF	CITATIONS
55	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
56	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	13.7	290
57	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	2.1	289
58	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
59	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
60	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	0.8	278
61	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	1.3	269
62	High response rate to PD-1 blockade in desmoplastic melanomas. <i>Nature</i> , 2018, 553, 347-350.	13.7	269
63	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	5.1	266
64	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600E Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	0.8	266
65	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	15.2	256
66	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
67	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017, 28, 1130-1136.	0.6	253
68	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	3.2	253
69	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1 Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	3.2	249
70	Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 936-940.	15.2	246
71	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	7.7	242
72	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	1.3	236

#	ARTICLE	IF	CITATIONS
73	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
74	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	3.4	229
75	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600 Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
76	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 643-654.	5.1	224
77	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
78	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383.	0.8	216
79	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology, The</i> , 2017, 18, 1202-1210.	5.1	211
80	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017, 47, 789-802.e9.	6.6	207
81	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous <i>BRAF</i> Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology, The</i> , 2015, 16, 1389-1398.	5.1	206
82	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	5.8	205
83	Long-Term Outcomes in Patients With <i>BRAF</i> V600 Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	0.8	196
84	Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 169-178.	1.8	196
85	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after <i>BRAF</i> inhibitors. <i>Cancer</i> , 2014, 120, 1695-1701.	2.0	195
86	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	3.2	192
87	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
88	Cutaneous toxicities of <i>RAF</i> inhibitors. <i>Lancet Oncology, The</i> , 2013, 14, e11-e18.	5.1	190
89	Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four <i>BRAF</i> and <i>MEK</i> Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 567-574.	3.2	185
90	Resistance to combination <i>BRAF</i> and <i>MEK</i> inhibition in metastatic melanoma: Where to next?. <i>European Journal of Cancer</i> , 2016, 62, 76-85.	1.3	178

#	ARTICLE	IF	CITATIONS
91	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
92	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
93	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2013, 19, 4868-4878.	3.2	167
94	Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020, 11, 1897.	5.8	165
95	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2012, 167, 1153-1160.	1.4	163
96	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1 α and Oxidative Phosphorylation in Melanoma. <i>Cancer Research</i> , 2014, 74, 7037-7047.	0.4	161
97	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	1.3	160
98	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
99	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	2.9	150
100	WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2877-2890.	3.9	144
101	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	7.7	141
102	Assessment of nivolumab exposure and clinical safety of 480 μ g every 4 weeks flat-dosing schedule in patients with cancer. <i>Annals of Oncology</i> , 2018, 29, 2208-2213.	0.6	139
103	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
104	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. <i>Molecular Oncology</i> , 2011, 5, 124-136.	2.1	135
105	Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 2035-2043.	3.2	135
106	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
107	A case report of clonal EBV-like memory CD4 ⁺ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	15.2	133
108	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131

#	ARTICLE	IF	CITATIONS
109	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	0.6	131
110	Systemic treatment for BRAF-mutant melanoma: where do we go next?. <i>Lancet Oncology</i> , The, 2014, 15, e371-e381.	5.1	130
111	Targeting BRAF for patients with melanoma. <i>British Journal of Cancer</i> , 2011, 104, 392-398.	2.9	129
112	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4697-4709.	0.4	126
113	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	5.1	126
114	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2016, 5, e1214788.	2.1	123
115	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	15.2	121
116	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	3.2	120
117	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
118	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9503-9503.	0.8	116
119	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. <i>Science Signaling</i> , 2015, 8, ra82.	1.6	114
120	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2016, 114, 1084-1089.	2.9	113
121	Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. <i>Oncolmmunology</i> , 2016, 5, e1238557.	2.1	113
122	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
123	The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. <i>European Journal of Endocrinology</i> , 2018, 178, 173-180.	1.9	111
124	Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. <i>JAMA Oncology</i> , 2021, 7, 744.	3.4	110
125	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
126	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109

#	ARTICLE	IF	CITATIONS
127	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107
128	Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	0.8	107
129	BRAF inhibitor activity in V600R metastatic melanoma. <i>European Journal of Cancer</i> , 2013, 49, 1073-1079.	1.3	105
130	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 836-847.	5.1	104
131	Dabrafenib and its potential for the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2012, 6, 391.	2.0	102
132	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	5.8	102
133	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. <i>Nature Cancer</i> , 2021, 2, 693-708.	5.7	102
134	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	1.3	100
135	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. <i>Molecular Oncology</i> , 2014, 8, 544-554.	2.1	98
136	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3704-e3713.	1.8	98
137	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9508-9508.	0.8	98
138	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	1.3	97
139	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. <i>European Journal of Cancer</i> , 2017, 75, 169-178.	1.3	96
140	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016, 27, 1940-1946.	0.6	94
141	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	5.1	94
142	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	2.9	93
143	Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 414-424.	7.7	91
144	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	3.2	91

#	ARTICLE	IF	CITATIONS
145	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	2.9	91
146	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> -Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	0.8	90
147	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680.	2.7	86
148	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. <i>Nature Communications</i> , 2020, 11, 2408.	5.8	86
149	Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5499-5506.	1.8	85
150	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
151	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
152	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020, 368, 1127-1131.	6.0	83
153	Title is missing!. , 2017, , .		82
154	Residual ¹⁸ F-FDG- ¹⁸ F-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 572-577.	1.5	81
155	Targeting Adenosine in <i>BRAF</i> -Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
156	SIRT6 haploinsufficiency induces <i>BRAF</i> ^{V600E} melanoma cell resistance to MAPK inhibitors via IGF signalling. <i>Nature Communications</i> , 2018, 9, 3440.	5.8	80
157	Epigenetic Changes of EGFR Have an Important Role in <i>BRAF</i> Inhibitor-Resistant Cutaneous Melanomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 532-541.	0.3	79
158	Epigenetic profiling for the molecular classification of metastatic brain tumors. <i>Nature Communications</i> , 2018, 9, 4627.	5.8	79
159	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019, 7, 559-571.	1.6	79
160	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. <i>Immunity</i> , 2020, 53, 805-823.e15.	6.6	79
161	Intratumoral Molecular Heterogeneity in a <i>BRAF</i> -Mutant, <i>BRAF</i> Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2704-2708.	1.9	78
162	Characteristics of pyrexia in <i>BRAF</i> ^{V600E/K} metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. <i>Annals of Oncology</i> , 2015, 26, 415-421.	0.6	78

#	ARTICLE	IF	CITATIONS
163	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3132-3141.	0.8	78
164	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78
165	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	1.5	77
166	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. <i>Annals of Oncology</i> , 2019, 30, 815-822.	0.6	77
167	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544.	2.9	76
168	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
169	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. <i>Annals of Oncology</i> , 2021, 32, 917-925.	0.6	76
170	Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9568-9568.	0.8	76
171	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	3.2	75
172	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1332-1342.	1.9	71
173	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
174	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
175	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9503-9503.	0.8	71
176	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 504-508.	0.6	70
177	Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 607-610.	1.5	70
178	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	3.2	70
179	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.4	69
180	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	1.3	69

#	ARTICLE	IF	CITATIONS
181	Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PLoS ONE, 2014, 9, e85004.	1.1	67
182	Inpatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	2.1	66
183	The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition. Cancer, 2014, 120, 3142-3153.	2.0	65
184	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 2019, 116, 148-157.	1.3	64
185	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	7.7	64
186	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. Oncoimmunology, 2020, 9, 1659093.	2.1	62
187	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Annals of Oncology, 2020, 31, 1075-1082.	0.6	62
188	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. European Journal of Cancer, 2021, 157, 214-224.	1.3	62
189	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncoimmunology, 2019, 8, e1537581.	2.1	61
190	Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib. Australasian Journal of Dermatology, 2014, 55, 250-254.	0.4	60
191	Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients. Clinical Cancer Research, 2015, 21, 98-105.	3.2	60
192	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 2020, 16, 4429-4438.	1.1	59
193	Prognostic Gene Expression Profiling in Cutaneous Melanoma. JAMA Dermatology, 2020, 156, 1004.	2.0	59
194	Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Current Opinion in Oncology, 2017, 29, 484-492.	1.1	58
195	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i>-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	3.2	57
196	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 2021, 144, 182-191.	1.3	57
197	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncology, The, 2021, 22, 370-380.	5.1	57
198	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. Journal of Clinical Oncology, 2020, 38, 10002-10002.	0.8	57

#	ARTICLE	IF	CITATIONS
199	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	3.2	56
200	LBA43 Spaltalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020, 31, S1172.	0.6	56
201	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. <i>British Journal of Cancer</i> , 2013, 108, 924-931.	2.9	55
202	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. <i>Cell Death and Disease</i> , 2013, 4, e914-e914.	2.7	55
203	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	5.1	55
204	Molecular Genomic Profiling of Melanocytic Nevus. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768.	0.3	55
205	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060.	2.3	54
206	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	13.7	54
207	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 3671-3681.	3.2	53
208	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	0.8	53
209	Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 385-398.	2.0	51
210	KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. <i>Annals of Oncology</i> , 2018, 29, viii442.	0.6	51
211	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	1.5	51
212	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
213	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 4064-4071.	3.2	50
214	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017, 7, 832-851.	7.7	49
215	Immune mediated neuropathy following checkpoint immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 14-17.	0.8	49
216	Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998.	3.2	48

#	ARTICLE	IF	CITATIONS
217	Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.. Journal of Clinical Oncology, 2016, 34, 3014-3014.	0.8	48
218	Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.. Journal of Clinical Oncology, 2016, 34, 9502-9502.	0.8	47
219	First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer, 2020, 126, 4926-4935.	2.0	46
220	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
221	Paradoxical oncogenesis: are all BRAF inhibitors equal?. Pigment Cell and Melanoma Research, 2013, 26, 611-615.	1.5	44
222	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. Journal of Clinical Oncology, 2016, 34, 9504-9504.	0.8	44
223	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
224	Treatment of Melanoma Brain Metastases. Cancer Journal (Sudbury, Mass), 2012, 18, 208-212.	1.0	43
225	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	0.8	43
226	¹⁸ F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 2013, 49, 395-402.	1.3	42
227	Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. Melanoma Research, 2014, 24, 468-474.	0.6	42
228	Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 2013, 169, 1310-1313.	1.4	41
229	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 2020, 26, 5926-5933.	3.2	41
230	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.. Journal of Clinical Oncology, 2012, 30, 8510-8510.	0.8	41
231	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European Journal of Cancer, 2013, 49, 3229-3241.	1.3	40
232	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	2.0	40
233	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
234	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	1.3	40

#	ARTICLE	IF	CITATIONS
235	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF ^{V600E/K} mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9011-9011.	0.8	40
236	Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. <i>Cancer</i> , 2014, 120, 530-536.	2.0	39
237	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 809-815.e1.	0.6	39
238	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. <i>Pathology</i> , 2016, 48, 261-266.	0.3	39
239	Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma. <i>Molecular Cancer Research</i> , 2019, 17, 1435-1449.	1.5	39
240	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
241	Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 499-508.	1.5	37
242	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	2.9	37
243	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
244	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021, 155, 268-280.	1.3	37
245	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016, 115, 1280-1284.	2.9	36
246	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, e602-e605.	1.9	35
247	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/ β -Catenin Signaling. <i>PLoS ONE</i> , 2014, 9, e94748.	1.1	35
248	Facial Palsy As a Side Effect of Vemurafenib Treatment in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e215-e217.	0.8	34
249	Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 404-410.	1.5	34
250	Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 509-515.	1.5	34
251	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 9500-9500.	0.8	34
252	Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3176-3181.	0.8	33

#	ARTICLE	IF	CITATIONS
253	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017, 5, 32.	2.8	33
254	Tumour gene expression signature in primary melanoma predicts long-term outcomes. <i>Nature Communications</i> , 2021, 12, 1137.	5.8	33
255	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
256	Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. <i>Internal Medicine Journal</i> , 2015, 45, 1066-1073.	0.5	32
257	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1680-1692.	1.9	32
258	Phase 1b/2 trial of ribociclib+binimetinib in metastatic <i>NRAS</i> -mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9519-9519.	0.8	32
259	Novel adjuvant options for cutaneous melanoma. <i>Annals of Oncology</i> , 2021, 32, 854-865.	0.6	31
260	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced <i>BRAF</i> V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9531-9531.	0.8	31
261	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. <i>Oncotarget</i> , 2014, 5, 10127-10139.	0.8	31
262	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019, 10, 930-941.	0.8	31
263	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1782-1789.	0.7	30
264	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C <i>BRAF</i> V600 mutant melanoma. <i>Annals of Oncology</i> , 2017, 28, v432.	0.6	30
265	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
266	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2021, 10, 1875639.	2.1	30
267	Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9506-9506.	0.8	30
268	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. <i>Cancer</i> , 2012, 118, 4519-4529.	2.0	29
269	Germline BAP1 -positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. <i>European Journal of Cancer</i> , 2018, 92, 48-53.	1.3	29
270	Leptomeningeal melanoma—A case series in the era of modern systemic therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 120-124.	1.5	29

#	ARTICLE	IF	CITATIONS
271	New <i>RAS</i> -Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e52-e56.	0.8	28
272	<i>BRAF</i> ^{V600E} and <i>NRAS</i> ^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016, 69, 680-686.	1.6	28
273	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti- <i>PD-1</i> antibodies. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 553-563.	1.5	28
274	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1904-1911.	3.2	28
275	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). <i>Cancer Research</i> , 2021, 81, CT004-CT004.	0.4	28
276	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	1.3	28
277	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. <i>Oncolimmunology</i> , 2012, 1, 997-999.	2.1	27
278	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 3247-3258.	3.2	27
279	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
280	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	1.7	27
281	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27
282	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	2.9	27
283	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 278-285.	1.4	26
284	The molecular profile of metastatic melanoma in Australia. <i>Pathology</i> , 2016, 48, 188-193.	0.3	26
285	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. <i>Lancet Oncology</i> , 2016, 17, 1037-1039.	5.1	26
286	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. <i>Annals of Oncology</i> , 2017, 28, v428.	0.6	26
287	Preliminary findings from part 1 of COMBI-i: A phase III study of anti- <i>PD-1</i> antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 189-189.	0.8	26
288	Ipilimumab (IPI) alone or in combination with anti- <i>PD-1</i> (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to <i>PD1</i> monotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 10005-10005.	0.8	26

#	ARTICLE	IF	CITATIONS
289	Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. <i>Journal of Clinical Oncology</i> , 2016, 34, e17-e20.	0.8	25
290	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. <i>Pituitary</i> , 2018, 21, 274-282.	1.6	25
291	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. <i>Pathology</i> , 2019, 51, 39-45.	0.3	25
292	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. <i>Cancers</i> , 2021, 13, 1363.	1.7	24
293	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8501-8501.	0.8	24
294	A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with <i>BRAF V600</i>-mutant solid tumors and melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9518-9518.	0.8	24
295	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 393-398.	1.8	24
296	A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). , 2015, 3, .		23
297	Histopathology of pembrolizumab-induced hepatitis: a case report. <i>Pathology</i> , 2017, 49, 789-792.	0.3	23
298	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
299	Optimizing combination dabrafenib and trametinib therapy in BRAF mutationâ€‘positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 5-12.	0.7	22
300	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	1.7	22
301	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
302	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 2624-2635.	3.2	22
303	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	0.6	22
304	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 393-398.	1.8	22
305	Association of Antithyroid Antibodies in Checkpoint Inhibitorâ€‘Associated Thyroid Immuneâ€‘Related Adverse Events. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1843-e1849.	1.8	22
306	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	0.6	22

#	ARTICLE	IF	CITATIONS
307	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 693-704.	1.1	21
308	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. <i>British Journal of Cancer</i> , 2021, 124, 156-160.	2.9	21
309	The tumour immune landscape and its implications in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 529-549.	1.5	21
310	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	3.2	21
311	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. <i>Annals of Oncology</i> , 2021, 32, S1314-S1315.	0.6	21
312	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10000-10000.	0.8	21
313	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
314	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.4	21
315	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	0.8	20
316	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. <i>Lancet Oncology</i> , The, 2015, 16, e522-e526.	5.1	20
317	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	1.1	20
318	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20
319	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. <i>Frontiers in Immunology</i> , 2020, 11, 372.	2.2	20
320	Systemic therapies for melanoma brain metastases: which drug for whom and when?. <i>Chinese Clinical Oncology</i> , 2015, 4, 25.	0.4	20
321	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335.	2.2	20
322	The role of systemic therapies in the management of melanoma brain metastases. <i>Current Opinion in Oncology</i> , 2014, 26, 222-229.	1.1	19
323	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. <i>Pathology</i> , 2014, 46, 193-198.	0.3	19
324	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19

#	ARTICLE	IF	CITATIONS
325	Adverse events 2.0”Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
326	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in <i>BRAF^{V600E}</i> melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8503-8503.	0.8	19
327	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
328	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014, 27, 1193-1202.	2.9	18
329	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	0.6	18
330	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
331	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10015-10015.	0.8	18
332	Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
333	Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. <i>Science Translational Medicine</i> , 2022, 14, eabj9779.	5.8	18
334	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 5215-5221.	3.2	17
335	Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. <i>European Journal of Cancer Care</i> , 2017, 26, e12600.	0.7	17
336	Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. <i>Cancers</i> , 2021, 13, 1740.	1.7	17
337	Synthesis, properties and complexation studies on 3-amino-6,6-dimethyl-2,2-bipyridine. <i>Journal of the Chemical Society Dalton Transactions</i> , 1993, , 3175-3180.	1.1	16
338	Solution conformation of the antitumor drug streptonigrin. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 3056-3060.	2.9	16
339	BRAF inhibitor activity in V600R metastatic melanoma – Response. <i>European Journal of Cancer</i> , 2013, 49, 1797-1798.	1.3	16
340	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	1.6	16
341	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. <i>European Journal of Cancer</i> , 2021, 142, 10-17.	1.3	16
342	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021, 148, 51-57.	1.3	16

#	ARTICLE	IF	CITATIONS
343	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	0.8	16
344	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
345	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. Annals of Oncology, 2016, 27, vi381.	0.6	15
346	Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy. Annals of Oncology, 2017, 28, 434-435.	0.6	15
347	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15
348	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer, 2021, 153, 234-241.	1.3	15
349	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 2022, 33, 99-106.	0.6	15
350	24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma. European Journal of Cancer, 2015, 51, S722.	1.3	14
351	Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006. European Journal of Cancer, 2017, 72, S122-S123.	1.3	14
352	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. Laboratory Investigation, 2017, 97, 176-186.	1.7	14
353	CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-“LAG-3) in combination with nivolumab (anti-“PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. Annals of Oncology, 2018, 29, viii464-viii465.	0.6	14
354	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	1.7	14
355	Genetic drivers of non-“cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Experimental Dermatology, 2022, 31, 13-30.	1.4	14
356	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021, 31, 181-185.	0.6	14
357	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	1.3	14
358	CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. New England Journal of Medicine, 2022, 386, 1668-1669.	13.9	14
359	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	1.6	13
360	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Frontiers in Immunology, 2021, 12, 672521.	2.2	13

#	ARTICLE	IF	CITATIONS
361	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
362	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> V600 mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9010-9010.	0.8	13
363	First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3029-3029.	0.8	13
364	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	12
365	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
366	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	1.3	12
367	Updated overall survival (OS) results for BRF113220, a phase 1-2 study of dabrafenib alone versus combined dabrafenib and trametinib in patients with <i>BRAF</i> V600 metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9036-9036.	0.8	12
368	Activity of targeted therapy after failure of first-line immunotherapy in <i>BRAF</i> -mutant metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9532-9532.	0.8	12
369	Optimal systemic therapy for high-risk resectable melanoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 431-439.	12.5	12
370	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
371	Computer-assisted diagnosis for skin cancer: have we been outsmarted?. <i>Lancet, The</i> , 2017, 389, 1962-1964.	6.3	11
372	Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. <i>European Journal of Cancer</i> , 2017, 82, 167-170.	1.3	11
373	Clinical significance of intronic variants in <i>BRAF</i> inhibitor resistant melanomas with altered <i>BRAF</i> transcript splicing. <i>Biomarker Research</i> , 2017, 5, 17.	2.8	11
374	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
375	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to <i>BRAF</i> Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 757.	1.3	11
376	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/ Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	1.7	11
377	Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with <i>TP53</i> wild type (<i>TP53WT</i>) metastatic cutaneous melanoma (MCM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2575-2575.	0.8	11
378	Preliminary results from the international neoadjuvant melanoma consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9581-9581.	0.8	11

#	ARTICLE	IF	CITATIONS
379	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1607-1616.	0.3	11
380	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	5.1	10
381	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9515-9515.	0.8	10
382	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with <i>BRAF</i> V600 mutant (mut) melanoma brain metastases (MBM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9506-9506.	0.8	10
383	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9545-9545.	0.8	10
384	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition – A Descriptive Observational Retrospective Multicenter Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 765608.	1.3	10
385	A proton nuclear magnetic resonance study of the interaction of zinc(II) with the antitumour drug streptonigrin. <i>Journal of the Chemical Society Dalton Transactions</i> , 1996, , 549.	1.1	9
386	X-ray structure of the zinc complex of the central metal chelation site of the antitumour drug streptonigrin. <i>Polyhedron</i> , 2000, 19, 1067-1071.	1.0	9
387	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. <i>British Journal of Cancer</i> , 2014, 111, 1678-1679.	2.9	9
388	Multiple checkpoints on the long road towards cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2015, 93, 323-325.	1.0	9
389	OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). <i>Annals of Oncology</i> , 2018, 29, viii734.	0.6	9
390	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. <i>British Journal of Cancer</i> , 2018, 119, 713-723.	2.9	9
391	Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. <i>Melanoma Research</i> , 2021, 31, 482-486.	0.6	9
392	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9583-9583.	0.8	9
393	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III <i>BRAF</i>-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	0.8	9
394	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10087-TPS10087.	0.8	9
395	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
396	3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma. <i>European Journal of Cancer</i> , 2015, 51, S664.	1.3	8

#	ARTICLE	IF	CITATIONS
397	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. <i>Pathology</i> , 2018, 50, 648-653.	0.3	8
398	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. <i>Annals of Oncology</i> , 2020, 31, S734-S735.	0.6	8
399	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021, 27, 4500-4510.	3.2	8
400	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	0.7	8
401	Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBI-i. <i>Cancer Research</i> , 2018, 78, CT182-CT182.	0.4	8
402	KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9513-9513.	0.8	8
403	Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9517-9517.	0.8	8
404	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9604-TPS9604.	0.8	8
405	Ipilimumab-induced hypophysitis: early Australian experience. <i>Medical Journal of Australia</i> , 2014, 201, 198-199.	0.8	8
406	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
407	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. <i>Annals of Oncology</i> , 2018, 29, viii456.	0.6	7
408	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e367.	5.1	7
409	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. <i>Pathology</i> , 2021, 53, 830-835.	0.3	7
410	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	1.3	7
411	Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9534-9534.	0.8	7
412	Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600 mutant unresectable or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9505-9505.	0.8	7
413	PIVOT-12: a phase III study of adjuvant bempedalesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. <i>Future Oncology</i> , 2022, 18, 903-913.	1.1	7
414	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. <i>European Journal of Cancer</i> , 2015, 51, S666.	1.3	6

#	ARTICLE	IF	CITATIONS
415	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. Applied Sciences (Switzerland), 2019, 9, 5074.	1.3	6
416	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	0.8	6
417	Targeting the Microbiome to Overcome Resistance. Cancer Cell, 2021, 39, 151-153.	7.7	6
418	Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study.. Journal of Clinical Oncology, 2016, 34, TPS3106-TPS3106.	0.8	6
419	A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).. Journal of Clinical Oncology, 2016, 34, TPS9591-TPS9591.	0.8	6
420	A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).. Journal of Clinical Oncology, 2016, 34, TPS9598-TPS9598.	0.8	6
421	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. Journal of Clinical Oncology, 2017, 35, 9512-9512.	0.8	6
422	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 2020, 11, 4016-4027.	0.8	6
423	Double Trouble: Immunotherapy Doublets in Melanomaâ€”Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 745-766.	1.8	6
424	Recent Developments in Melanoma Therapy. JAMA Oncology, 2016, 2, 1259.	3.4	5
425	The â€œTricky Businessâ€•of Identifying Mechanisms of Resistance to Antiâ€”PD-1. Clinical Cancer Research, 2017, 23, 2921-2923.	3.2	5
426	Radiological manifestations of immuneâ€”related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 2017, 61, 759-766.	0.9	5
427	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.1	5
428	Perspectives in melanoma: meeting report from the â€œMelanoma Bridgeâ€•(December 5thâ€”7th, 2019,) Tj ETQq0,0 0 rgBT /Overlock	1.8	5
429	Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlentherapie Und Onkologie, 2021, 197, 1104-1112.	1.0	5
430	Distinct patterns of response and toxicity (tox) by sites of metastases (mets) in patients (pts) treated with ipilimumab combined with PD-1 antibodies (ipi+PD1).. Journal of Clinical Oncology, 2018, 36, 9553-9553.	0.8	5
431	Antitumor Activity of Ipilimumab or BRAF \pm MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 2021, , .	0.6	5
432	Copper(II) bipyridyl and iminopyridyl analogues of streptonigrin. Journal of the Chemical Society Dalton Transactions, 1995, , 3905.	1.1	4

#	ARTICLE	IF	CITATIONS
433	The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 1-15.	0.7	4
434	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?. <i>Melanoma Management</i> , 2015, 2, 15-19.	0.1	4
435	Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. <i>Annals of Oncology</i> , 2018, 29, viii451-viii452.	0.6	4
436	Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. <i>New England Journal of Medicine</i> , 2019, 380, 1374-1377.	13.9	4
437	LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN- γ sign): The DONIMI study. <i>Annals of Oncology</i> , 2021, 32, S1315.	0.6	4
438	Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9596-TPS9596.	0.8	4
439	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9513-9513.	0.8	4
440	Neurotoxicity associated with anti-PD1 therapy: A multi-center case series.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21641-e21641.	0.8	4
441	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9600-TPS9600.	0.8	4
442	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. <i>Investigational New Drugs</i> , 2022, 40, 1051-1065.	1.2	4
443	3-Amino-6,6-bis(methoxycarbonyl)-2,2-bipyridine, a model for the central chelation unit of streptonigrin. <i>Journal of the Chemical Society Dalton Transactions</i> , 1995, , 951-955.	1.1	3
444	Reply to M. Perier-Muzet et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3203-3204.	0.8	3
445	Optimum dosing of ipilimumab in melanoma: too little, too late?. <i>Lancet Oncology</i> , The, 2017, 18, 558-559.	5.1	3
446	Adjuvant Therapy in Resected Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 678-680.	13.9	3
447	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
448	Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018, 29, viii446.	0.6	3
449	A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). <i>Annals of Oncology</i> , 2018, 29, viii465-viii466.	0.6	3
450	Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy. <i>Internal Medicine Journal</i> , 2022, 52, 818-827.	0.5	3

#	ARTICLE	IF	CITATIONS
451	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. <i>Australasian Journal of Dermatology</i> , 2021, 62, 168-176.	0.4	3
452	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. <i>BMC Cancer</i> , 2021, 21, 1014.	1.1	3
453	Primary medical therapy for BRAFV600E-mutant melanoma brain metastases—“is this good enough?” Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e509.	5.1	3
454	Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012, 30, e19011-e19011.	0.8	3
455	Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9077-9077.	0.8	3
456	NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic <i>NRAS</i> -mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS9102-TPS9102.	0.8	3
457	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	0.8	3
458	An app to increase cross-referral and recruitment to melanoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9590-9590.	0.8	3
459	CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9601-TPS9601.	0.8	3
460	Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. <i>Australian Journal of General Practice</i> , 2020, 49, 355-362.	0.3	3
461	Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8558-8558.	0.8	3
462	Successful treatment of eruptive keratoacanthomas with actitrein for patients on checkpoint inhibitor immunotherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
463	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
464	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. <i>Medical Journal of Australia</i> , 2022, 217, 208-209.	0.8	3
465	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. <i>Pathology</i> , 2022, 54, 533-540.	0.3	3
466	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. <i>Medical Journal of Australia</i> , 2015, 202, 115-116.	0.8	2
467	Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006. <i>European Journal of Cancer</i> , 2017, 72, S128-S129.	1.3	2
468	Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018, 29, viii445.	0.6	2

#	ARTICLE	IF	CITATIONS
469	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019, 30, v543-v544.	0.6	2
470	Neoadjuvant immunotherapy in melanoma - the new frontier. <i>Clinical Cancer Research</i> , 2021, 27, clincanres.1236.2021.	3.2	2
471	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	5.1	2
472	Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. <i>Pathology</i> , 2022, 54, 369-371.	0.3	2
473	Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naïve advanced melanoma. , 2015, , .		2
474	Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. , 2019, , .		2
475	PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9527-9527.	0.8	2
476	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9541-9541.	0.8	2
477	Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9545-9545.	0.8	2
478	Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9546-9546.	0.8	2
479	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	1.3	2
480	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<sc>MelCOR</sc>): A modified Delphi study. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.4	2
481	Is chemotherapy still an option in the treatment of melanoma?. <i>Annals of Oncology</i> , 2015, 26, 2203-2204.	0.6	1
482	Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600E mutant melanoma. <i>Annals of Oncology</i> , 2016, 27, vi389.	0.6	1
483	Triple jeopardy for people with albinism. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 487-487.	1.5	1
484	Reply to – Comment on – Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy – TM. <i>British Journal of Cancer</i> , 2017, 116, e15-e15.	2.9	1
485	Management of melanoma recurrence following adjuvant anti-PD1 therapy. <i>Annals of Oncology</i> , 2018, 29, viii446-viii447.	0.6	1
486	Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. <i>Annals of Oncology</i> , 2018, 29, viii448.	0.6	1

#	ARTICLE	IF	CITATIONS
487	Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas. British Journal of Cancer, 2018, 119, 661-662.	2.9	1
488	Reply to E. HindiÃ© and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	0.8	1
489	Novel Immune Targets in Melanomaâ€™Response. Clinical Cancer Research, 2019, 25, 5424-5425.	3.2	1
490	bcGSTâ€™an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics, 2019, 35, 1350-1357.	1.8	1
491	Reply to E. HindiÃ©. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
492	Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma. ANZ Journal of Surgery, 2021, , .	0.3	1
493	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	1.3	1
494	Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM).. Journal of Clinical Oncology, 2015, 33, e20005-e20005.	0.8	1
495	The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.. Journal of Clinical Oncology, 2016, 34, 9566-9566.	0.8	1
496	BRAF/MEK inhibition in melanoma patients with rare BRAF mutations.. Journal of Clinical Oncology, 2018, 36, 9542-9542.	0.8	1
497	Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 10050-10050.	0.8	1
498	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 2022, 63, .	0.4	1
499	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 2022, , .	0.3	1
500	Reflectance confocal microscopy â€™ a nonâ€™invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	1
501	Multiple eruptive squamoproliferative lesions during antiâ€™PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. Dermatologic Therapy, 2022, , e15472.	0.8	1
502	Clinicopathologic Features of V600E and V600K Melanomaâ€™Response. Clinical Cancer Research, 2012, 18, 6793-6793.	3.2	0
503	Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, E635.	0.4	0
504	3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). European Journal of Cancer, 2015, 51, S682-S683.	1.3	0

#	ARTICLE	IF	CITATIONS
505	Brain Metastases from Melanoma. , 2016, , 65-83.		0
506	Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E710-E711.	0.4	0
507	Welcome to the New Year!. Pigment Cell and Melanoma Research, 2016, 29, 3-3.	1.5	0
508	Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials. Annals of Oncology, 2016, 27, vi388.	0.6	0
509	Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600 mutant metastatic melanoma in the COMBI-d and COMBI-v trials. Annals of Oncology, 2016, 27, vi390.	0.6	0
510	Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy. Annals of Oncology, 2018, 29, viii659.	0.6	0
511	Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. Annals of Oncology, 2018, 29, viii444.	0.6	0
512	Making a difference to many. Nature Medicine, 2019, 25, 356-356.	15.2	0
513	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	0.8	0
514	Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis. European Journal of Cancer, 2019, 110, S21-S22.	1.3	0
515	Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9004-9004.	0.8	0
516	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation positive melanoma with metastases to the brain (BRV116521).. Journal of Clinical Oncology, 2014, 32, TPS9112-TPS9112.	0.8	0
517	Abstract IA30: Combined targeted therapies, where to next. , 2015, , .		0
518	Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance. , 2015, , .		0
519	Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition. , 2016, , .		0
520	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. Journal of Clinical Oncology, 2017, 35, 51-51.	0.8	0
521	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. Journal of Clinical Oncology, 2017, 35, 9558-9558.	0.8	0
522	Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
523	PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study.. Journal of Clinical Oncology, 2018, 36, 183-183.	0.8	0
524	A case series of immune checkpoint inhibitor induced diabetes mellitus (ICI-DM).. Journal of Clinical Oncology, 2018, 36, e22080-e22080.	0.8	0
525	Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial. , 2018, , .		0
526	Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing. , 2018, , .		0
527	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. Journal of Translational Medicine, 2022, 20, 200.	1.8	0
528	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. Melanoma Research, 2022, Publish Ahead of Print, .	0.6	0